App-Quantinova.ai

Serum Calprotectin Can Differentiate Between Sustained Remission and Low Disease Activity States in Rheumatoid Arthritis

Margaret Ma - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous Systemic Sclerosis

Francesco Del Galdo - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pulmonary arterial hypertension

Interferon

Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Yann Nguyen - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus

Hydroxychloroquine

Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey

Ashima Makol - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Should Independence Play a Role in Assessing Remission in Rheumatoid Arthritis?

Thomas Khoo - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Single Antiphospholipid Antibody Positive Thrombotic APS Patients’ Clinical Characteristics: Retrospective Results from the APS ACTION Clinical Database and Repository (Registry)

Silvia Grazietta Foddai - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Single Cell and Spatial Transcriptomics Identifies Pathogenic Drivers of Sjogren’s Disease in Humans

Blake Warner - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Single Cell Atlas of Minor Salivary Glands Reveals Key Differential Cellular and Functional Players in Sjögren’s and Sicca Syndrome

SABA NAYAR - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

N/A

Single-Cell Characterization of the TCR Repertoire Across Tissue and Blood in Rheumatoid Arthritis

Garrett Dunlap - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Single-cell Profiling of B Cell Repertoire and Gene Expression in the RA Synovium Reveals Tissue Specific Clonal Expansion

Aaron Wagner - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

Christopher Ritchlin - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

Methotrexate

Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial

William Tillett - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

guselkumab (IV)

Structural Differences Exist in Beta-2-Glycoprotein I from APS Patients Compared to Healthy Controls

Thomas McDonnell - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Supernatants from Activated Macrophages Contain Citrullinated Vimentin and Induce Extracellular Matrix Deposition from Fibroblasts

nozima Aripova - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

citrulline

Survey to Prioritize and Generate Domains in Preparation to Update the OMERACT Core Domain Set for Systemic Lupus Erythematosus

Wils Nielsen - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

Iain B McInnes - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

guselkumab (IV)

Systemic Lupus Erythematosus Women with Lupus Nephritis in Pregnancy Therapeutic CHallenge (SWITCH): The Systemic Lupus International Collaborating Clinics Experience

Joo Young (Esther) Lee - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus

Mycophenolate mofetil

Systemic Sclerosis Dermal Fibroblast-derived Exosomes Trigger a Type 1 Interferon Rresponse in Keratinocytes Through TBK1

Jessica Bryon - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Interferon

Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients

Costantino Pitzalis - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Technetium tc 99m tilmanocept

Telemedicine Use in the Assessment of Juvenile Dermatomyositis and Polymyositis: A Survey of Caregivers and Patients

Stacey Tarvin - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Juvenile dermatomyositis

N/A

Filters

45280 Abstracts